You can save this article by registering for free here. Or sign-in if you have an account.
Article content
U.S. regulators have approved AstraZeneca Plc’s Imfinzi treatment for use against an aggressive type of lung cancer in previously untreated patients, the group said on Monday, as it moves to expand its specialization in tackling the disease.
The treatment, when combined with chemotherapy, was approved by the U.S. Food and Drug Administration for adult patients with extensive-stage small cell lung cancer, the British drugmaker said.
AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancerBack to video
AstraZeneca has already carved out a niche for Imfinzi, which enables the immune system to detect and attack certain cancer cells, in the more common non-small cell lung cancer (NSCLC) setting, with approval for tumors that have only spread in the chest.
Advertisement 2
Story continues below
This advertisement has not loaded yet, but your article continues below.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, Victoria Wells and others.
Daily content from Financial Times, the world's leading global business publication.
Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, Victoria Wells and others.
Daily content from Financial Times, the world's leading global business publication.
Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
Access articles from across Canada with one account.
Share your thoughts and join the conversation in the comments.
Merck & Co’s immunotherapy bestseller Keytruda has become the standard treatment option for the larger group of NSCLC patients that are diagnosed at a more advanced stage of the disease.
In the small-cell type of cancer, Astra is seeking to catch up with Roche, whose immunotherapy Tecentriq won U.S. approval for the disease type a year ago.
Small cell lung cancer is a highly aggressive, fast-growing form of cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.
Lung cancer is the leading cause of cancer deaths among both men and women, accounting for about one fifth of all deaths from the disease. (Reporting by Ludwig Burger in Frankfurt and Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta and Jan Harvey)
Article content
Share this article in your social network
Share this Story : AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer
Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.
This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Service and Privacy Policy.
Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.